Eur J Clin Pharmacol. 1987;32(6):635-7.
Differential efficacy of mebendazole and albendazole against Necator americanus but not for Trichuris trichiura infestations.

Holzer BR, Frey FJ.

Medizinische Poliklinik, University of Berne, Switzerland.

The effect of single oral doses of albendazole 600 mg and mebendazole 1 g given to 56 and 60 men, respectively, with T. trichiura and/or N. americanus infestation has been studied. Both albendazole and mebendazole cured more than 90% of T. trichiura infestations, but only albendazole (95%) and not mebendazole (21%) had a high cure rate for N. americanus infestations. Thus, albendazole is the preferred benzimidazole derivate for the mass treatment of subjects with T. trichiura and/or N. americanus infestations.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3653234&dopt=Abstract albendazole Albenza




Br J Surg. 1987 Sep;74(9):805-6.
Pre-operative albendazole therapy for hydatid cyst.

Morris DL.

Department of Surgery, University Hospital, Nottingham, UK.

Surgical management of hydatid cyst is associated with recurrence in 10 per cent of patients. The role of perioperative chemotherapy in prevention of recurrence has not been extensively explored. Sixteen patients with Echinoccus granulosus were treated with albendazole 10 mg kg-1 before operation; of fourteen patients who received albendazole for 1 month or more before operation only one (with doubtful therapeutic compliance) had viable protoscoleces, in contrast both of the two remaining patients who received only 1 and 3 weeks therapy had live disease at the time of operation. A 1 month pre-operative course of albendazole kills most if not all protoscoleces within hydatid cysts in man. This may allow pre-operative 'sterilization' of cysts and a reduction in the risk of recurrence.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3664246&dopt=Abstract albendazole Albenza




Southeast Asian J Trop Med Public Health. 1987 Jun;18(2):207-10.
Albendazole in the treatment of strongyloidiasis.

Pungpak S, Bunnag D, Chindanond D, Radmoyos B.

Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Albendazole was used to treat 30 patients with Strongyloides stercoralis infections. There were 21 males and 9 females, 13 to 68 years of age, who were divided into two groups of 11 and 19, respectively. Repeated pre- and post-treatment stool examinations were done by simple direct smear and formalin-ether concentration, and larval quantitations were done by the Stoll and Sasa's technique. Group I patients were given albendazole in dosages of 400 mg/day in divided doses for 3 days. Group II patients were given similar dosages, but were treated again 7 days later on the same schedule. Patients in Group I were followed for 14 days and those in Group II for 30 days. The cure rates were 73% for Group I and 100% for Group II. Side effects were minimal and transient. Albendazole is recommended for the treatment of strongyloidiasis in dosages of 400 mg/day in divided doses for 3 days with treatment repeated one week later.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3672182&dopt=Abstract albendazole Albenza




Vet Res Commun. 1986 Jul;10(4):317-24.
Sulfoxidation of albendazole by a cytochrome P450-independent monooxygenase from rat liver microsomes.

Fargetton X, Galtier P, Delatour P.

The in vitro biological oxidation of albendazole to albendazole sulfoxide by rat liver microsomes has been studied. This reaction corresponds to a NADPH-dependent enzymatic system, characterised by Km and Vm values of 53.6 microM and 0.59 nmole/mg protein per min. The rate of sulfoxidation by liver microsomes of rats treated with phenobarbital, B-naphthoflavone, Aroclor 1254 and 3-methylcholanthrene was not increased. SKF 525A and metyrapone did not inhibit albendazole sulfoxidase. Thiobenzamide and tranylcypromine decreased sulfoxidation to 48 and 52% of control values. The inhibition by tranylcypromine was competitive. Purified flavin adenine dinucleotide (FAD)-containing monooxygenase from hog liver microsomes catalysed sulfoxidation of albendazole (V = 0.52 nmole/nmole enzyme per min). The present data demonstrate that sulfoxidation of albendazole in the rat liver is not catalysed by a cytochrome P450-dependent monooxygenase and suggest that albendazole is a substrate for FAD-containing monooxygenase (FMO).

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3739217&dopt=Abstract albendazole Albenza




Eur J Clin Pharmacol. 1986;30(6):705-8.
Pharmacokinetics of albendazole in man.

Marriner SE, Morris DL, Dickson B, Bogan JA.

The pharmacokinetics of albendazole were investigated in healthy volunteers and in patients receiving albendazole for treatment of hydatid disease. Unchanged albendazole was below detectable limits in plasma, urine, bile and cyst fluid. The major metabolite present in all fluids was the sulfoxide. Maximum concentrations of albendazole sulfoxide in plasma were very variable, probably due to variable absorption of albendazole.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3770064&dopt=Abstract albendazole Albenza




Trans R Soc Trop Med Hyg. 1986;80(3):481-4.
Can albendazole reduce the risk of implantation of spilled protoscoleces? An animal study.

Morris DL, Chinnery JB, Hardcastle JD.

Post-operative recurrence of hydatid disease occurs in approximately 10% of patients. The role of pre- or post-spillage chemotherapy with albendazole (10 mg/kg) was investigated in a gerbil model. All animals received approximately 5000 protoscoleces of ovine Echinococcus granulosus by intraperitoneal injection. Pre-spillage albendazole therapy did not protect against the development of cysts whilst a significant reduction in numbers of peritoneal cysts was seen in gerbils treated with albendazole 10 mg/kg for one week after inoculation. Two weeks therapy was no more effective. A very short course of albendazole treatment immediately following intraperitoneal 'spillage' of protoscoleces in a gerbil significantly reduced the number of cysts which developed. This finding may well be of clinical value.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3798546&dopt=Abstract albendazole Albenza




Arch Intern Med. 1987 Apr;147(4):738-41.
Albendazole therapy for neurocysticercosis.

Escobedo F, Penagos P, Rodriguez J, Sotelo J.

Seven patients with chronic parenchymal brain cysticercosis were treated with albendazole for one month at daily doses of 15 mg/kg of body weight. Computed tomographic follow-up studies were made at the following times: a mean of 16 months before the trial; the beginning of treatment; the end of treatment; and three months afterward. Computed tomographic studies at the beginning of treatment showed a total of 157 cysts, the last day of treatment the number had decreased to 39 cysts, and three months later, the total number of lesions was 22; this represents 86% improvement in the number of cystic lesions. Control studies in the same group of patients had shown chronic persistence of lesions without spontaneous improvement in most cases. Two patients had been treated with praziquantel previously with partial response; in both cases albendazole therapy was effective with 100% and 77% improvement. We conclude that albendazole is highly effective for the treatment of parenchymal brain cysticercosis. It is also effective in patients who had shown poor therapeutic response to praziquantel.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3827462&dopt=Abstract albendazole Albenza